Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings by Meintjes, Graeme et al.
Tuberculosis-associated immune reconstitution inflammatory
syndrome: case definitions for use in resource-limited settings
Graeme Meintjes, Stephen D Lawn, Fabio Scano, Gary Maartens, Martyn A French, William
Worodria, Julian H Elliott, David Murdoch, Robert J Wilkinson, Catherine Seyler, Laurence
John, Maarten Schim van der Loeff, Peter Reiss, Lut Lynen, Edward N Janoff, Charles
Gilks, and Robert Colebunders for the International Network for the Study of HIV-
associated IRIS
Institute of Infectious Diseases and Molecular Medicine and Department of Medicine (G Meintjes
FCP[SA], R J Wilkinson FRCP), Desmond Tutu HIV Centre, Institute for Infectious Disease and
Molecular Medicine, Faculty of Health Sciences (S D Lawn MD), and Division of Clinical
Pharmacology, Department of Medicine (G Maartens FCP[SA]), University of Cape Town, Cape
Town, South Africa; Clinical Research Unit, Department of Infectious and Tropical Diseases,
London School of Hygiene and Tropical Medicine, London, UK (S D Lawn); HTM/STB/THD,
WHO, Geneva, Switzerland (F Scano MD); Department of Clinical Immunology, Royal Perth
Hospital and School of Pathology and Laboratory Medicine, University of Western Australia,
Perth, Australia (M A French MD); Infectious Diseases Institute, Makerere University, Uganda (W
Worodria MD); National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia (J
H Elliott MD); Duke University Medical Center, Durham, and University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA (D Murdoch MD); National Institute for Medical Research,
London, UK (R J Wilkinson); Wellcome Trust Center for Research in Clinical Tropical Medicine,
Division of Medicine, Imperial College London, UK (R J Wilkinson); Institut de Santé Publique,
d’Épidémiologie et de Développement (ISPED), Bordeaux 2 University, Bordeaux, France (C
Seyler MD); Chelsea and Westminster Hospital, London, UK (L John MRCP); Center for Poverty-
related Communicable Diseases, Academic Medical Centre, Amsterdam, Netherlands (M Schim
van der Loeff MD, P Reiss MD); Institute of Tropical Medicine, Antwerp, Belgium (L Lynen MD, R
Colebunders MD); Colorado Center for AIDS Research, University of Colorado at Denver and
Health Sciences Center, Denver Veterans Affairs Medical Center, Denver, CO, USA (E N Janoff
MD); HIV Department, WHO, Geneva, Switzerland (C Gilks FRCP); and Faculty of Medicine,
University of Antwerp, Antwerp, Belgium (R Colebunders)
Abstract
The immune reconstitution inflammatory syndrome (IRIS) has emerged as an important early
complication of antiretroviral therapy (ART) in resource-limited settings, especially in patients
with tuberculosis. However, there are no consensus case definitions for IRIS or tuberculosis-
associated IRIS. Moreover, previously proposed case definitions are not readily applicable in
settings where laboratory resources are limited. As a result, existing studies on tuberculosis-
associated IRIS have used a variety of non-standardised general case definitions. To rectify this
problem, around 100 researchers, including microbiologists, immunologists, clinicians,
epidemiologists, clinical trialists, and public-health specialists from 16 countries met in Kampala,
Uganda, in November, 2006. At this meeting, consensus case definitions for paradoxical
tuberculosis-associated IRIS, ART-associated tuberculosis, and unmasking tuberculosis-associated
IRIS were derived, which can be used in high-income and resource-limited settings. It is
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envisaged that these definitions could be used by clinicians and researchers in a variety of settings
to promote standardisation and comparability of data.
Introduction
The immune reconstitution inflammatory syndrome (IRIS; also known as immune
reconstitution disease, immune reconstitution syndrome, or immune restoration disease) is a
widely recognised phenomenon that can complicate antiretroviral therapy (ART).1,2 The
condition results from rapid restoration of pathogen-specific immune responses to
opportunistic infections, causing either the deterioration of a treated infection or the new
presentation of a previously subclinical infection. IRIS typically occurs during the initial
months of ART and is associated with a wide spectrum of pathogens, most commonly
mycobacteria, herpes-viruses, and deep fungal infections such as cryptococcal meningitis.1–3
In recent years, access to ART has increased rapidly in resource-limited settings, reaching
over 2 million people by December, 2006, with an estimated 1 340 000 of these individuals
living in sub-Saharan Africa.4 Since the burden of HIV/tuberculosis co-infection is very
high in many low-income and middle-income countries,5 many of the patients who enter
ART programmes in these settings have a current diagnosis of tuberculosis, or later develop
tuberculosis following initiation of ART. For example, one South African study reported
that 238 (25%) of 944 patients attending a community-based ART programme were
receiving tuberculosis treatment at ART initiation and in the first year of ART the incidence
of tuberculosis was 13·4 cases per 100 person-years (95% CI 10·4–16·9).6 Up to one-third
of patients with HIV/tuberculosis co-infection who begin ART in such settings could be at
risk of developing tuberculosis-associated IRIS (also known as TB-IRIS),3 and this
condition is emerging as an important clinical challenge in resource-limited settings.7–10
Since there is no diagnostic test for IRIS, confirmation of the disease relies heavily upon
case definitions incorporating clinical and laboratory data. However, clinical management
and research on IRIS are hindered by the lack of consensus case definitions and definitions
that are specific to particular opportunistic infections. To address this shortcoming, an
international meeting of researchers working in this field was convened in Kampala,
Uganda, in November, 2006, and the International Network for the Study of HIV-associated
IRIS (INSHI) was formed. The specific aim of the meeting was to develop consensus case
definitions for tuberculosis-associated IRIS that are appropriate for low-income settings
where laboratory capacity is often limited, and that can be used by researchers working in
dierent settings to permit comparability of results. We present these consensus case
definitions in this paper.
Participants and consensus methods
The need for a public-health definition for tuberculosis-associated IRIS was first proposed at
the WHO consultation on tuberculosis and HIV research priorities in resource-limited
settings in February, 2005.11 The organisers of the meeting in Kampala contacted
individuals involved in research related to tuberculosis-associated IRIS, particularly those
working in resource-limited settings or collaborating with researchers in these settings.
Contacting these individuals was dependent on whether they had published or presented data
about tuberculosis-associated IRIS at international conferences, whether they were involved
in ongoing research projects about the disease, or whether they had clinical experience of the
disease. 97 researchers from 16 countries on six continents attended the meeting. Among the
delegates were microbiologists, immunologists, clinicians, epidemiologists, clinical trialists,
public-health specialists, and representatives from WHO.
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At the meeting a subgroup was assembled to develop the case definitions. Two participants
presented published IRIS case definitions (panel 1)2,7,12–14 as well as eight dierent
tuberculosis-associated IRIS case definitions currently being used by researchers in ongoing
cohort and intervention studies. The common features among these case definitions were
highlighted, and their practical use in resource-limited settings was discussed. Tuberculosis-
associated IRIS case definitions were agreed and taken back to a plenary session for further
discussion and consensus building. Thereafter,
Panel 1
Existing case definitions for IRIS and tuberculosis-associated IRIS that
have been most widely used
General IRIS case definition 1 (French et al, 2004)2
Diagnosis requires two major criteria (A+B) or major criterion (A) plus two minor
criteria to be fulfilled:
Major criteria
(A) Atypical presentation of opportunistic infections or tumours in patients responding to
ART
• Localised disease
• Exaggerated inflammatory reaction
• Atypical inflammatory response in affected tissues
• Progressive organ dysfunction or enlargement of pre-existing lesions after
definite clinical improvement with pathogen-specific therapy before the
initiation of ART and exclusion of treatment toxicity and new alternative
diagnoses
(B) Decrease in plasma HIV RNA concentration by more than 1 log10 copies per mL
Minor criteria
• Increase in blood CD4 T-cell count after starting ART
• Increase in an immune response specific to the relevant pathogen—eg, delayed-
type hypersensitivity skin test response to mycobacterial antigens
• Spontaneous resolution of disease without specific antimicrobial therapy or
tumour chemotherapy with continuation of ART
General IRIS case definition 2 (Shelburne et al, 2006)13
Criteria for IRIS diagnosis include:
• HIV-infected patient
• Receiving effective ART as evidenced by a decrease in HIV-1 RNA
concentration from baseline or an increase in CD4+ T cells from baseline (may
lag behind HIV-1 RNA decrease)
• Clinical symptoms consistent with inflammatory process
• Clinical course not consistent with expected course of previously diagnosed
opportunistic infection, expected course of newly diagnosed opportunistic
infection, or drug toxicity
Case definition specific for tuberculosis-associated IRIS (Colebunders et al, 2006)7
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For patients receiving treatment for tuberculosis and starting ART:
Suspected tuberculosis-associated IRIS case
Cases must meet the following three criteria:
• An initial clinical response to tuberculosis treatment, based on a combination of
some of the following factors: cessation of fever, relief of pulmonary symptoms,
decrease in lymph node size, termination of signs of meningeal irritation
(depending on presenting symptoms)
• New persistent fevers without another identifiable cause and/or one or more of
the following: worsening or emergence of dyspnoea, stridor, an increase in
lymph node size, development of abscesses, development of abdominal pain
with ultrasound evidence of abdominal adenopathies, unexplained CNS
symptoms
• Adequate adherence to ART and tuberculosis treatment
Confirmed tuberculosis-associated IRIS case
Cases must meet the following three criteria:
• Radiological examinations showing worsening or emergence of intrathoracic
lymphadenopathy, pulmonary infiltrates, pleural effusions, abdominal lymph
nodes, hepatosplenomegaly
• A good virological response and/or increase in CD4+ lymphocyte count, and/or
conversion of tuberculin skin test from negative to positive, and/or adequate
adherence to ART and tuberculosis treatment
• A clear exclusion of other conditions that could explain the clinical
manifestations of the patient, such as tuberculosis treatment failure or other
concomitant infections, tumours, or allergic reactions
ART=antiretroviral therapy. IRIS=immune reconstitution inflammatory syndrome.
a writing committee of 17 members was appointed to finalise the consensus case definitions.
Changes to existing case definitions
General case definitions for IRIS have previously been published (panel 1).2,12–14 These
case definitions include the following criteria: confirmed HIV diagnosis, temporal
association with initiation of ART, demonstration of response to ART (ie, plasma viral load
reduction, blood CD4 cell count increase, or another marker of immune recovery such as
conversion of tuberculin skin test from negative to positive for mycobacterial IRIS), clinical
deterioration with an inflammatory process, and exclusion of other causes that could explain
deterioration (such as antimicrobial drug resistance, drug hypersensitivity reaction, or
another opportunistic infection). However, since manifestations of IRIS are infection-
specific, it has been recognised that particular definitions applicable to individual diseases
such as tuberculosis would be useful.7 The case definitions presented in this manuscript
focus specifically on the clinical manifestations of tuberculosis-associated IRIS.
Case definitions should be readily applicable in resource-limited settings where the vast
majority of patients requiring ART live and yet where facilities for diagnosis and
management of the complications of ART are least well developed. In this respect, the
requirement within existing definitions for documentation of changes in CD4 cell count and
plasma viral load is not achievable in these settings. Viral load testing has limited
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availability and is very costly. In the South African public sector a viral load test costs US
$39, more than the cost of 1 month’s supply of first-line ART. Even where CD4 and viral
load testing are available (such as in South Africa), use of these tests under programmatic
conditions is usually permitted for monitoring of ART at 6-monthly intervals only and not
for individual patient diagnostic work-up.
We believe that omission of these laboratory parameters would not substantially
compromise case definitions for tuberculosis-associated IRIS. First, within the initial months
of ART—when most cases of tuberculosis-associated IRIS arise—most ART-naive patients
adhering to treatment have substantial viral load reductions;15–17 thus, inclusion of viral load
changes in definitions is largely redundant in the context of a patient who adheres to
therapy. Second, tuberculosis-associated IRIS frequently develops shortly after initiation of
ART and before any measurable increase in peripheral blood CD4 cell count. In a series of
51 patients presenting with non-tuberculous mycobacterial IRIS, six (12%) of 51 IRIS
events occurred without a substantial increase in CD4 cell count (four patients had a CD4
increase from baseline to time of IRIS diagnosis of less than 25 cells per μL and in two
patients the CD4 cell count had actually fallen at the time of presentation).18 The number of
CD4 T cells measured in peripheral blood does not necessarily reflect function nor how
many cells are actually present at the site of an opportunistic infection. Moreover, it is very
likely that CD4 T cells are not the only cellular mediators of IRIS.19,20 For these reasons
we, like others,12 propose that a rise in peripheral blood CD4 cell count should not be a
necessary marker for the diagnosis of tuberculosis-associated IRIS.
A further important modification to existing definitions is the inclusion of a timeframe of the
first 3 months of ART. Such a timeframe is not present in the widely used case definitions to
date (panel 1). Onset of the clinical manifestations of tuberculosis-associated IRIS should
occur within this timeframe for a diagnosis of tuberculosis-associated IRIS to be made, since
this represents the period when rapid immune recovery usually occurs.3,21
Categories of tuberculosis-associated IRIS
Tuberculosis-associated IRIS can present as one of two main syndromes: (1) a paradoxical
reaction after the start of ART in patients receiving tuberculosis treatment (here termed
paradoxical tuberculosis-associated IRIS), or (2) a new presentation of tuberculosis that is
“unmasked” in the weeks following initiation of ART with an exaggerated inflammatory
clinical presentation or complicated by a paradoxical reaction (here termed unmasking
tuberculosis-associated IRIS).
Paradoxical tuberculosis-associated IRIS
In paradoxical tuberculosis-associated IRIS, patients have been diagnosed with active
tuberculosis before initiation of ART, and have typically been responding to antituberculosis
treatment. Following initiation of ART, IRIS presents as the development of recurrent, new,
or worsening symptoms or signs of tuberculosis, such as fever, return of cough, or lymph
node enlargement, or recurrent, new, or deteriorating radiological manifestations (figure 1).
These symptoms typically occur within the first few weeks and up to 3 months after ART is
initiated, restarted, or changed because of treatment failure.
Reports of the frequency of paradoxical tuberculosis-associated IRIS using a variety of
existing case definitions range from 8% to 43% (table).8–10,21–28 Paradoxical tuberculosis-
associated IRIS has been linked with large expansions of purified protein derivative-specific
T cells in peripheral blood and increased pro-inflammatory cytokine levels.29 Risk factors
for the disease are shown in table 1 and include more advanced HIV disease with lower CD4
cell count, disseminated and extrapulmonary tuberculosis, a shorter delay between the start
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of tuberculosis treatment and initiation of ART, and a more vigorous immunological and
virological response to ART. Most cases of paradoxical tuberculosis-associated IRIS are
self-limiting. The median duration of symptoms reported in the literature is 2 months,26,28
but this ranges from mild cases where symptoms resolve after a few days to isolated
prolonged cases that have still been symptomatic after more than a year (figure 1).28
Mortality from tuberculosis-associated IRIS has been reported infrequently in the literature,
3,9,10,26 but morbidity and the need for hospital admission and therapeutic procedures can
be substantial.26 Rates of morbidity and mortality attributable to paradoxical tuberculosis-
associated IRIS may be higher in resource-limited settings where diagnostic and treatment
options are restricted. Neurological tuberculosis-associated IRIS in particular can be
associated with poor outcome.
Tuberculosis paradoxical reactions, such as enlargement of lymph nodes or cerebral
tuberculomas, can also occur in HIV-uninfected individuals and HIV-infected individuals
who are receiving appropriate tuberculosis treatment but who are not receiving ART;30–32
however, the frequency of paradoxical reactions is much lower in these groups compared
with patients receiving ART.22,23 In one study, paradoxical reactions following
tuberculosis treatment occurred in one (2%) of 55 HIV-seronegative patients, two (7%) of
28 HIV-infected patients not on ART, and 12 (36%) of 33 HIV-infected patients on
tuberculosis treatment and ART.22 The timing of the paradoxical reaction in the latter group
was more closely related to the initiation of ART than it was to the initiation
Panel 2
Case definition for paradoxical tuberculosis-associated IRIS
There are three components to this case definition:
(A) Antecedent requirements
Both of the two following requirements must be met:
• Diagnosis of tuberculosis: the tuberculosis diagnosis was made before starting
ART and this should fulfil WHO criteria for diagnosis of smear-positive
pulmonary tuberculosis, smear-negative pulmonary tuberculosis, or
extrapulmonary tuberculosis44
• Initial response to tuberculosis treatment: the patient’s condition should have
stabilised or improved on appropriate tuberculosis treatment before ART
initiation—eg, cessation of night sweats, fevers, cough, weight loss. (Note: this
does not apply to patients starting ART within 2 weeks of starting tuberculosis
treatment since insufficient time may have elapsed for a clinical response to be
reported)
(B) Clinical criteria
The onset of tuberculosis-associated IRIS manifestations should be within 3 months of
ART initiation, reinitiation, or regimen change because of treatment failure.
Of the following, at least one major criterion or two minor clinical criteria are required:
Major criteria
• New or enlarging lymph nodes, cold abscesses, or other focal tissue
involvement—eg, tuberculous arthritis
• New or worsening radiological features of tuberculosis (found by chest
radiography, abdominal ultrasonography, CT, or MRI)
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• New or worsening CNS tuberculosis (meningitis or focal neurological deficit—
eg, caused by tuberculoma)
• New or worsening serositis (pleural effusion, ascites, or pericardial effusion)
Minor criteria
• New or worsening constitutional symptoms such as fever, night sweats, or
weight loss
• New or worsening respiratory symptoms such as cough, dyspnoea, or stridor
• New or worsening abdominal pain accompanied by peritonitis, hepatomegaly,
splenomegaly, or abdominal adenopathy
(C) Alternative explanations for clinical deterioration must be excluded if possible*
• Failure of tuberculosis treatment because of tuberculosis drug resistance
• Poor adherence to tuberculosis treatment
• Another opportunistic infection or neoplasm (it is particularly important to
exclude an alternative diagnosis in patients with smear-negative pulmonary
tuberculosis and extrapulmonary tuberculosis where the initial tuberculosis
diagnosis has not been microbiologically confirmed)
• Drug toxicity or reaction
ART=antiretroviral therapy. IRIS=immune reconstitution inflammatory syndrome. *It
might be difficult or impossible in resource-poor settings to confirm tuberculosis drug
resistance and to exclude certain other infections or neoplasia. Cases where alternative
diagnoses cannot be fully excluded because of limited diagnostic capacity should be
regarded as “probable paradoxical tuberculosis-associated IRIS”. In these probable cases,
should resolution of clinical or radiological findings of the suspected IRIS episode occur
without a change in tuberculosis treatment or ART having been made, they could then be
reclassified as ”paradoxical tuberculosis-associated IRIS” cases.
of tuberculosis treatment. Thus, the greatly increased frequency of paradoxical reactions in
patients receiving ART suggests that ART-related immunological changes have an
important role in their aetiology. Additionally, our clinical experience is that paradoxical
tuberculosis-associated IRIS is more severe and more frequently a multisystemic condition
in ART patients than paradoxical reactions in patients not receiving ART.
ART-associated tuberculosis and unmasking tuberculosis-associated IRIS
Compared with paradoxical tuberculosis-associated IRIS, there is much less clarity
surrounding the second major category of tuberculosis-associated-IRIS. High rates of
tuberculosis have been diagnosed during ART, especially in the initial months of treatment
in ART programmes in resource-limited settings.6,33–36 The mechanisms underlying the
presentation of tuberculosis after the initiation of ART are likely to be heterogeneous.37
Since ART-induced immune recovery is a time-dependent process and some patients
initially fail to show an increased circulating CD4 T-cell count,38,39 a proportion of cases
might present as a result of persisting immunodeficiency. Diagnoses of active tuberculosis
before ART initiation might be missed because of the inherent insensitivity of tuberculosis
diagnostics in patients with advanced immunodeficiency and only confirmed later during
ART. Other patients might have active subclinical disease at the time of ART initiation and
presentation of symptomatic disease might result from ART-induced restoration of an
immune response against Mycobacterium tuberculosis antigens that causes inflammation.
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Some patients with a missed tuberculosis diagnosis or active subclinical tuberculosis at the
time of ART initiation may later present with exuberant inflammatory clinical features that
are consistent with a diagnosis of unmasking tuberculosis-associated IRIS (figure 2).
Paradoxical reactions in patients started on tuberculosis treatment while receiving ART have
also been described,26,40 and one study reported that paradoxical reactions are more
frequent in patients who are diagnosed with tuberculosis in the first 3 months of ART than
in patients who start ART after tuberculosis treatment (eight [62%] of 13 patients vs nine
[30%] of 30 patients, respectively, p=0·05).40 This finding suggests that ART-related
immunological changes have a role in the development of paradoxical reactions in patients
who present with tuberculosis while receiving ART and that these reactions are a form of
tuberculosis-associated IRIS.
Only a few cases of unmasking tuberculosis-associated IRIS have been described in the
literature to date.40–43 In the absence of a diagnostic test, it is currently difficult to
dierentiate the varied mechanisms underlying most cases of tuberculosis that present during
early ART, especially in resource-limited settings where rates of infection are high. We
therefore propose that, as elsewhere,37 the term ART-associated tuberculosis is used
Panel 3
Case definition for ART-associated tuberculosis and provisional case
definition for unmasking tuberculosis-associated IRIS
ART-associated tuberculosis
We propose that ART-associated tuberculosis (all cases of tuberculosis that are
diagnosed during ART) should be defined as follows:
• Patient is not receiving treatment for tuberculosis when ART is initiated
• Active tuberculosis is diagnosed after initiation of ART
• The diagnosis of tuberculosis should fulfil WHO criteria for smear-positive
pulmonary tuberculosis, smear-negative pulmonary tuberculosis, or
extrapulmonary tuberculosis44
Unmasking tuberculosis-associated IRIS (provisional)
We propose that the following could suggest a diagnosis of unmasking tuberculosis-
associated IRIS:
• Patient is not receiving treatment for tuberculosis when ART is initiated and
then presents with active tuberculosis within 3 months of starting ART
AND one of the following criteria must be met:
• Heightened intensity of clinical manifestations, particularly if there is evidence
of a marked inflammatory component to the presentation. Examples include
tuberculosis lymphadenitis or tuberculosis abscesses with prominent acute
inflammatory features, presentation with pulmonary tuberculosis that is
complicated by respiratory failure due to adult respiratory distress syndrome,
and those who present with a marked systemic inflammatory syndrome related
to tuberculosis. See example in figure 2
• Once established on tuberculosis treatment, a clinical course that is complicated
by a paradoxical reaction
Meintjes et al. Page 8













ART=antiretroviral therapy. IRIS=immune reconstitution inflammatory syndrome.
Researchers in the field are encouraged not to regard all patients with ART-associated
tuberculosis as having tuberculosis-associated IRIS, but only those that fit this
provisional unmasking tuberculosis-associated-IRIS case definition. We suggest that the
clinical manifestations of all patients developing ART-associated tuberculosis should be
well characterised and reported in studies, which will assist with refinement of this case
definition in the future. Studies of the immunological processes underlying the
presentation of these cases are also likely to assist with refining this case definition.
to refer to all patients who present with active tuberculosis while receiving ART (figure 3).
We also suggest a provisional case definition for unmasking tuberculosis-associated IRIS
and clinical scenarios where the diagnosis could be considered.
Further research into the clinical characteristics and immunological mechanisms underlying
cases of ART-associated tuberculosis will permit a more refined case definition for
unmasking tuberculosis-associated IRIS in the future. However, in view of the heterogeneity
in the natural history and clinical manifestations of tuberculosis it is unlikely that a clinical
case definition that robustly separates patients with unmasking tuberculosis-associated IRIS
from others with ART-associated tuberculosis will be derived.37
Case definitions
With the rationale described above, we have developed case definitions for “paradoxical
tuberculosis-associated IRIS” (panel 2), “ART-associated tuberculosis” (panel 3), and
“unmasking tuberculosis-associated-IRIS” (panel 3). The case definitions are presented
schematically in figure 3. These case definitions have been designed for use in resource-
limited settings and are consensus case definitions that need validation in clinical practice.
Search strategy and selection criteria
Data for this Personal View were obtained by searching Medline for articles published
from 1990 to 2008. Search terms included “immune reconstitution”, “immune
restoration”, “immune recovery”, “IRIS”, “antiretroviral”, “tuberculosis”, and
“paradoxical reaction”. Only English language papers were reviewed. Additionally,
unpublished data and tuberculosis-associated IRIS case definitions presented by
researchers at the INSHI meeting were used.
Conclusions
The use of standardised case definitions in different populations will help to provide greater
insight into the incidence, clinical manifestations, risk factors, and impact of tuberculosis-
associated IRIS, ultimately leading to better prevention and management strategies for this
condition. Further clinical and immunological research on patients with ART-associated
tuberculosis is needed to better dierentiate the subset of cases that have unmasking
tuberculosis-associated IRIS and to further refine this case definition. It is hoped that open
research networks such as INSHI will provide opportunities for researchers to engage in
collaborative research into tuberculosis-associated IRIS using these case definitions.
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Figure 1. Illustrative case of paradoxical tuberculosis-associated IRIS
A 36-year-old HIV-infected man was diagnosed with culture-positive pulmonary
tuberculosis (sensitive to rifampicin and isoniazid) without evidence of extrapulmonary
involvement. His CD4 count was 39 cells per μL and HIV-1 viral load 1 300 000 copies per
mL. He commenced antiretroviral therapy (ART; stavudine, lamivudine, and efavirenz) 7
weeks after initiating antituberculous therapy. 1 week later he presented with a recurrence of
tuberculosis symptoms and cervical node enlargement. Paradoxical tuberculosis-associated
IRIS was diagnosed. Over the next 18 months he presented with several tuberculosis-
associated IRIS manifestations that sequentially emerged, despite corticosteroid therapy,
then resolved. Photographs show development of massive cervical lymphadenitis (A), a
chest wall cold abscess (B, arrows), and a massive right psoas abscess shown here on CT
scan (C, arrow) from which over 2 L of pus was aspirated (D). Repeated mycobacterial
cultures of aspirates from these collections have been negative. After 6 months on ART his
CD4 count was 181 cells per μL and viral load undetectable. After 12 months his CD4 count
was 448 cells per μL and viral load 35 copies per mL. This was an unusually prolonged
course for paradoxical tuberculosis-associated IRIS given that the median duration of
symptoms is reported to be 2 months (see text).
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Figure 2. Illustrative case of unmasking tuberculosis-associated IRIS
A 48-year-old HIV-infected man with a CD4 count of 10 cells per μL presented with low-
grade fevers, retrosternal chest pain, and a dry cough. Examination was non-contributory.
He could not produce sputum and his chest radiograph showed no features of active
tuberculosis (A). No other investigations for tuberculosis were available in this resource-
limited setting (Uganda). Antiretroviral therapy (ART) was started (zidovudine, lamivudine,
and efavirenz). 10 days later he returned acutely unwell with a productive cough. His
temperature was 38·7°C and he was in respiratory distress. Chest radiograph now showed
left mid-zone consolidation (B) and his sputum was positive for acid-fast bacilli. The
unusual rapidity and clinical severity of his tuberculosis presentation was attributed to
unmasking tuberculosis-associated IRIS. He responded well to continued ART and
tuberculosis treatment.
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Figure 3. Schematic representation showing the different forms of tuberculosis-associated IRIS
and ART-associated tuberculosis
ART=antiretroviral therapy.
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